AZN ASTRAZENECA PLC
Price Chart
Executive Summary
AstraZeneca announced FDA approval of Enhertu (trastuzumab deruxtecan) for two new indications in HER2-positive early breast cancer: neoadjuvant (pre-surgery) treatment based on DESTINY-Breast11 Phase III trial, and adjuvant (post-surgery) treatment based on DESTINY-Breast05 Phase III trial. This expands Enhertu into the curative-intent early-stage setting, reinforcing its role across the HER2-positive breast cancer treatment continuum. A $155 million milestone payment is due from AstraZeneca to Daiichi Sankyo following these approvals.
Actionable Insight
This is a major label expansion for Enhertu into the curative-intent early breast cancer setting, significantly expanding the addressable patient population. The DESTINY-Breast05 data showing a 53% risk reduction in invasive disease recurrence is practice-changing and supports NCCN Category 1 recommendation. Monitor for rapid adoption in the neoadjuvant and adjuvant settings, and watch for regulatory decisions in other countries under Project Orbis. The $155M milestone is manageable for AstraZeneca's $56B+ market cap.
Key Facts
- FDA approved Enhertu for neoadjuvant treatment of HER2-positive Stage II/III early breast cancer (DESTINY-Breast11).
- FDA approved Enhertu for adjuvant treatment of HER2-positive early breast cancer with residual disease after neoadjuvant therapy (DESTINY-Breast05).
- DESTINY-Breast11 showed pCR rate of 67.3% vs 56.3% for standard care (improvement of 11.2%, p=0.003).
- DESTINY-Breast05 showed 53% reduction in risk of invasive disease recurrence or death vs T-DM1 (HR 0.47, p<0.0001); 92.4% vs 83.7% alive and free of invasive disease at 3 years.
- AstraZeneca owes Daiichi Sankyo $155 million in milestone payments for these two US approvals.
- Enhertu is now approved in the US across both early and metastatic HER2-positive breast cancer.
- No new safety concerns identified; ILD/pneumonitis rates were 9.6% in Enhertu arm vs 1.6% in T-DM1 arm in DESTINY-Breast05, with two Grade 5 events.
Financial Impact
$155 million milestone payment due from AstraZeneca to Daiichi Sankyo; revenue potential from expanded early-stage patient population (US breast cancer incidence ~320,000/year, ~20% HER2-positive).
Risk Factors
- ILD/pneumonitis safety signal persists (9.6% in adjuvant arm, including 2 Grade 5 deaths) which may limit adoption in some patients.
- Competition from other HER2-directed therapies (e.g., T-DM1, pertuzumab) and potential pricing pressure.
- Revenue recognition for US sales is by Daiichi Sankyo, not AstraZeneca; AstraZeneca's economics come from profit-sharing, not direct sales.
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-005038 |
| Document: 0001654954-26-005038-index-headers.html | 0001654954-26-005038 |
| Document: 0001654954-26-005038-index.html | 0001654954-26-005038 |
| Document: 0001654954-26-005038.txt | 0001654954-26-005038 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 1, 2026
8d ago
|
6-K
| $179.55 $185.95 | ▲ +3.57% | ▲ +6.32% | $183.43 (+2.16%) |
|
Jun 1, 2026
8d ago
|
6-K
| $179.55 $185.95 | ▲ +3.57% | ▲ +6.32% | $183.43 (+2.16%) |
|
May 29, 2026
11d ago
|
6-K
| $185.49 $185.93 | ▲ +0.24% | ▲ +2.76% | $183.43 (−1.11%) |
|
May 28, 2026
12d ago
|
25-NSE
| $185.34 $181.75 | ▼ −1.94% | ▼ −2.25% | $183.43 (−1.03%) |
|
May 27, 2026
13d ago
|
6-K
| $185.62 $176.10 | ▼ −5.13% | ▼ −5.60% | $183.43 (−1.18%) |
|
May 27, 2026
14d ago
|
Court Ruling
| $185.62 $177.45 | ▼ −4.40% | ▼ −5.61% | $183.43 (−1.18%) |
|
May 26, 2026
14d ago
|
6-K
| $187.11 $177.39 | ▼ −5.19% | ▼ −6.41% | $183.43 (−1.96%) |
|
May 26, 2026
14d ago
|
6-K
| $187.11 $177.39 | ▼ −5.19% | ▼ −6.41% | $183.43 (−1.96%) |
|
May 18, 2026
22d ago
|
6-K
| $183.91 $187.11 | ▲ +1.74% | ▲ +0.12% | $183.43 (−0.26%) |
|
May 18, 2026
22d ago
|
6-K
| $183.91 $187.11 | ▲ +1.74% | ▲ +0.12% | $183.43 (−0.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access